Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
NCT01331161
Completed
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vac... Read More
Gender:
ALL
Ages:
Between 25 years and 79 years
Trial Updated:
01/19/2016
Locations: University of Colorado, Aurora, Colorado +1 locations
Conditions: Shingles
Register for Updates
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children
NCT00262028
Completed
The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years
Gender:
ALL
Ages:
Between 12 months and 10 years
Trial Updated:
01/12/2016
Locations: Kaiser Permanente Vaccine Study Center, Oakland, California
Conditions: Prevention of Meningococcal Disease
Register for Updates
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
NCT01349647
Completed
Even when small cell lung cancer responds well to treatment with chemotherapy, it has a tendency to grow back and to spread. The investigators are interested in testing new therapies aimed at decreasing this risk. This study tests a vaccine, which is a substance injected under the skin which can cause an immune response. The hope is that the body will make antibodies to the vaccine which will also react against the cancer. The vaccine is specific for small cell lung cancer. It combines several c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lung Cancer
Register for Updates
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
NCT01255410
Completed
People who are infected with human metapneumovirus (HMPV) may develop upper and lower respiratory illnesses. Children are particularly sensitive to HMPV infection. This study will evaluate the safety and immune response of an HMPV vaccine in healthy adults, HMPV-seropositive children, and HMPV-seronegative infants and children.
Gender:
ALL
Ages:
Between 6 months and 49 years
Trial Updated:
12/14/2015
Locations: Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland +1 locations
Conditions: Metapneumovirus
Register for Updates
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
NCT01459198
Completed
Human respiratory syncytial virus (RSV) is a common cause of upper respiratory tract illnesses as well as more severe lower respiratory illnesses, including bronchiolitis and pneumonia. RSV affects almost all children within the first 2 years of life. This study will evaluate the safety and immune response to the RSV MEDI ΔM2-2 vaccine among adults, RSV-seropositive children, and RSV-seronegative infants and children.
Gender:
ALL
Ages:
Between 6 months and 49 years
Trial Updated:
12/14/2015
Locations: John Hopkins Center for Immunization Research, Baltimore, Maryland
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
NCT01674205
Completed
This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.
Gender:
ALL
Ages:
Between 18 years and 42 years
Trial Updated:
12/14/2015
Locations: University of Rochester Medical Center: Facility for Evaluation of Flu Vaccines, Rochester, New York
Conditions: Influenza, Human
Register for Updates
Phase II Tularemia Vaccine Comparison
NCT01150695
Completed
The purpose of this study is to compare 2 experimental vaccines that could provide protection from the disease, tularemia. This research will compare the ability of the vaccines to cause the body to develop an immune (protective) response and obtain more information on side effects of the vaccines. About 220 male and non-pregnant female volunteers 18 to 45 years will participate. Volunteers will be assigned to 1 of 2 vaccine groups by chance. About half of the volunteers will be placed in the DV... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/10/2015
Locations: Emory Vaccine Center - The Hope Clinic, Decatur, Georgia +4 locations
Conditions: Tularaemia
Register for Updates
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
NCT00003715
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: Cancer and Blood Institute of the Desert, Rancho Mirage, California +16 locations
Conditions: Melanoma (Skin)
Register for Updates
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
NCT00257465
Completed
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2015
Locations: University of Arizona Cancer Center, Tucson, Arizona +6 locations
Conditions: Melanoma
Register for Updates
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
NCT01023776
Completed
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
Gender:
ALL
Ages:
Between 18 years and 32 years
Trial Updated:
11/17/2015
Locations: Vaccine Research Unit Room 3-5000, Rochester, New York
Conditions: Influenza
Register for Updates
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
NCT00561756
Completed
RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Register for Updates
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
NCT00645411
Completed
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years. A step-down approach is utilized in which reactogenicity and safety will be assessed in children and adolescents 9 to 17 years of age (Cohort 1) prior to enrolling additional children and adolescents 9 to 17 years of age (Cohort 2) and children 3 to 8 years of age (Cohort 3).
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
10/20/2015
Locations: Site 09, Fayetteville, Arkansas +59 locations
Conditions: Influenza
Register for Updates